retatrutide trials weight loss (“reta”) is an experimental weight-loss drug currently in Phase 3 clinical trials. It's a once-weekly injection similar to Ozempic and Mounjaro—but more powerful. The reason comes down to how it works Seeking Differentiation Through a Triple

Nausea is the single most common side effect of GLP-1 receptor agonist medications and the most common reason patients in clinical trials and in clinic discontinue treatment

Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial

doi:10.1038/s41591-024-03018-2

Some common side effects of GLP-1 medications include: Nausea and vomiting Diarrhea Constipation Abdominal pain Loss of appetite Headaches Infection Irritation at the injection site Patients on GLP-1 therapies can also experience muscle loss or bone density loss with prolonged use, which can compound some of the natural physical changes that accompany menopause

As obesity management continues to evolve, retatrutide may help redefine expectations for both weight reduction and metabolic health outcomes